184 related articles for article (PubMed ID: 29936468)
1. Impressive Long-term Response with Pertuzumab and Trastuzumab in HER2-positive Breast Cancer with Brain Metastasis.
Russillo M; Ferretti G; Vidiri A; Gasparro S; Cognetti F; Pellegrini D; Fabi A
In Vivo; 2018; 32(4):839-842. PubMed ID: 29936468
[TBL] [Abstract][Full Text] [Related]
2. Pertuzumab, trastuzumab and docetaxel reduced the recurrence of brain metastasis from breast cancer: a case report.
Senda N; Yamaguchi A; Nishimura H; Shiozaki T; Tsuyuki S
Breast Cancer; 2016 Mar; 23(2):323-8. PubMed ID: 26116144
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of T-DM1 for leptomeningeal and brain metastases in a HER2 positive metastatic breast cancer patient: new directions for systemic therapy - a case report and literature review.
Ricciardi GRR; Russo A; Franchina T; Schifano S; Mastroeni G; Santacaterina A; Adamo V
BMC Cancer; 2018 Jan; 18(1):97. PubMed ID: 29370839
[TBL] [Abstract][Full Text] [Related]
4. Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer.
Yu AF; Manrique C; Pun S; Liu JE; Mara E; Fleisher M; Patil S; Jones LW; Steingart RM; Hudis CA; Dang CT
Oncologist; 2016 Apr; 21(4):418-24. PubMed ID: 26984450
[TBL] [Abstract][Full Text] [Related]
5. Combination of radiotherapy and double blockade HER2 with pertuzumab and trastuzumab for HER2-positive metastatic or locally recurrent unresectable and/or metastatic breast cancer: Assessment of early toxicity.
Ajgal Z; de Percin S; Diéras V; Pierga JY; Campana F; Fourquet A; Kirova YM
Cancer Radiother; 2017 Apr; 21(2):114-118. PubMed ID: 28347625
[TBL] [Abstract][Full Text] [Related]
6. HER2-positive metastatic breast cancer: a changing scenario.
Mustacchi G; Biganzoli L; Pronzato P; Montemurro F; Dambrosio M; Minelli M; Molteni L; Scaltriti L
Crit Rev Oncol Hematol; 2015 Jul; 95(1):78-87. PubMed ID: 25748080
[TBL] [Abstract][Full Text] [Related]
7. First-Line Palliative HER2-Targeted Therapy in HER2-Positive Metastatic Breast Cancer Is Less Effective After Previous Adjuvant Trastuzumab-Based Therapy.
Rier HN; Levin MD; van Rosmalen J; Bos MMEM; Drooger JC; de Jong P; Portielje JEA; Elsten EMP; Ten Tije AJ; Sleijfer S; Jager A
Oncologist; 2017 Aug; 22(8):901-909. PubMed ID: 28533475
[TBL] [Abstract][Full Text] [Related]
8. Clinical predictors of long-term survival in HER2-positive metastatic breast cancer.
Murthy P; Kidwell KM; Schott AF; Merajver SD; Griggs JJ; Smerage JD; Van Poznak CH; Wicha MS; Hayes DF; Henry NL
Breast Cancer Res Treat; 2016 Feb; 155(3):589-95. PubMed ID: 26875184
[TBL] [Abstract][Full Text] [Related]
9. Management of patients treated with pertuzumab in the Australian clinical practice setting.
Woodward N; White M; Pugliano L; Tsoi D; Ryan C
Asia Pac J Clin Oncol; 2016 Jun; 12 Suppl 2():5-15. PubMed ID: 27250913
[TBL] [Abstract][Full Text] [Related]
10. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial.
Gianni L; Pienkowski T; Im YH; Tseng LM; Liu MC; Lluch A; Starosławska E; de la Haba-Rodriguez J; Im SA; Pedrini JL; Poirier B; Morandi P; Semiglazov V; Srimuninnimit V; Bianchi GV; Magazzù D; McNally V; Douthwaite H; Ross G; Valagussa P
Lancet Oncol; 2016 Jun; 17(6):791-800. PubMed ID: 27179402
[TBL] [Abstract][Full Text] [Related]
11. Growth inhibition in a brain metastasis model by antibody delivery using focused ultrasound-mediated blood-brain barrier disruption.
Kobus T; Zervantonakis IK; Zhang Y; McDannold NJ
J Control Release; 2016 Sep; 238():281-288. PubMed ID: 27496633
[TBL] [Abstract][Full Text] [Related]
12. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.
Swain SM; Baselga J; Kim SB; Ro J; Semiglazov V; Campone M; Ciruelos E; Ferrero JM; Schneeweiss A; Heeson S; Clark E; Ross G; Benyunes MC; Cortés J;
N Engl J Med; 2015 Feb; 372(8):724-34. PubMed ID: 25693012
[TBL] [Abstract][Full Text] [Related]
13. Combination pertuzumab, trastuzumab, and taxane for metastatic breast cancer after first progression: a single institution's experience.
Dao BD; Ho H; Quintal LN
J Oncol Pharm Pract; 2016 Apr; 22(2):261-4. PubMed ID: 25802300
[TBL] [Abstract][Full Text] [Related]
14. Trastuzumab uptake and its relation to efficacy in an animal model of HER2-positive breast cancer brain metastasis.
Lewis Phillips GD; Nishimura MC; Lacap JA; Kharbanda S; Mai E; Tien J; Malesky K; Williams SP; Marik J; Phillips HS
Breast Cancer Res Treat; 2017 Aug; 164(3):581-591. PubMed ID: 28493046
[TBL] [Abstract][Full Text] [Related]
15. [A long-surviving case of HER2-positive breast cancer with brain metastasis treated by multidisciplinary therapy].
Sugimoto H; Nakagawa T; Sato T; Nagahara M; Ishiba T; Kasahara M; Kawachi H; Kubota K; Sugihara K
Gan To Kagaku Ryoho; 2012 Nov; 39(12):2071-3. PubMed ID: 23267980
[TBL] [Abstract][Full Text] [Related]
16. Pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.
Kawajiri H; Takashima T; Kashiwagi S; Noda S; Onoda N; Hirakawa K
Expert Rev Anticancer Ther; 2015 Jan; 15(1):17-26. PubMed ID: 25494663
[TBL] [Abstract][Full Text] [Related]
17. A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer.
Jhaveri K; Wang R; Teplinsky E; Chandarlapaty S; Solit D; Cadoo K; Speyer J; D'Andrea G; Adams S; Patil S; Haque S; O'Neill T; Friedman K; Esteva FJ; Hudis C; Modi S
Breast Cancer Res; 2017 Aug; 19(1):89. PubMed ID: 28764748
[TBL] [Abstract][Full Text] [Related]
18. Xeloda Oral, Trastuzumab, and Pertuzumab Combined Drug Therapy Reduced Cervical Lymphadenopathy and Dermal Involvement in Patient With Recurrent Breast Cancer: Case Report.
Saure Sarría VM; Arencibia AD; D'Afonseca V
J Investig Med High Impact Case Rep; 2020; 8():2324709620942606. PubMed ID: 32720808
[TBL] [Abstract][Full Text] [Related]
19. [Two Cases of Unresectable/Advanced Breast Cancer with Pathological Complete Response after Combination Chemotherapy with Pertuzumab. Trastuzumab, and Docetaxel].
Tomida K; Kawai Y; Mori T; Kitamura M; Kato H; Sakai S; Shimizu T; Umeda T; Tatsumi M; Shimada K; Tani M
Gan To Kagaku Ryoho; 2018 Dec; 45(13):2435-2437. PubMed ID: 30692489
[TBL] [Abstract][Full Text] [Related]
20. [A Case of HER2-Positive Breast Cancer with Newly Diagnosed Stage IV That Responded to First-Line Pertuzumab and Trastuzumab-Based Therapy].
Yoshioka S; Hojo S; Toyoda Y; Maeura Y
Gan To Kagaku Ryoho; 2017 Nov; 44(12):1214-1216. PubMed ID: 29394585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]